Q4 earnings fall for Orthofix but robust stimulation sales propel spinal growth
This article was originally published in Clinica
Executive Summary
Higher operating expenses led to a 24% drop in fourth-quarter earnings for Huntersville, North Carolina-based Orthofix International, with net income for that period falling from $9.5m in 2004 to $7.2m the following year. However, a windfall of $37.4m, which came from the settlement of a long-running lawsuit with Kinetic Concepts, propelled full-year profits for 2005 to $73.4m (+115%).
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.